Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.
Maturitas
; 148: 55-61, 2021 Jun.
Article
en En
| MEDLINE
| ID: mdl-33896654
INTRODUCTION: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. AIM: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. MATERIALS AND METHODS: Literature review and consensus of expert opinion. SUMMARY RECOMMENDATIONS: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Atrofia
/
Enfermedades Vaginales
/
Enfermedades de la Vulva
/
Guías de Práctica Clínica como Asunto
/
Posmenopausia
/
Estrógenos
Tipo de estudio:
Guideline
Aspecto:
Patient_preference
Límite:
Female
/
Humans
Idioma:
En
Revista:
Maturitas
Año:
2021
Tipo del documento:
Article
Pais de publicación:
Irlanda